MKI67 and neuroendocrine carcinoma: Extrapolation from the NORDIC NEC study suggests that G3 NET may be less responsive to first-line (typically platinum-based) chemotherapy than G3 NEC, based on the lower response rates and shorter survival seen in patients with Ki67 < 55% compared with Ki67 ≥ 55%, however, the proportion of these cases which are truly G3 NET cannot be determined12.